The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of rucaparib on circadian rhythms and adverse events in ovarian cancer: Insights from the MAMOC trial.
 
Deeksha Malhan
No Relationships to Disclose
 
Janina Hesse
No Relationships to Disclose
 
Nina Nelson
No Relationships to Disclose
 
Kay Stankov
No Relationships to Disclose
 
Jessica Nguyen
No Relationships to Disclose
 
Ouda Aboumanify
No Relationships to Disclose
 
Josefin Garmshausen
No Relationships to Disclose
 
Gunther Rogmans
Research Funding - North-East German Society for Gynecological Oncology (NOGGO) (Inst)
 
Bastian Czogalla
Honoraria - AstraZeneca
Consulting or Advisory Role - MSD
 
Jens Gerber
No Relationships to Disclose
 
Martin Koch
No Relationships to Disclose
 
Tomáš Kupec
No Relationships to Disclose
 
Oliver Tome
No Relationships to Disclose
 
Ralf Witteler
No Relationships to Disclose
 
Mustafa Deryal
No Relationships to Disclose
 
Michael Eichbaum
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Clovis Oncology; Corcept Therapeutics; Daiichi; Eisai; Esteve Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Hexal; Incyte; Jenapharm; Johnson & Johnson; Kyowa Kirin International; Medtronic Covidien; MSD Oncology; Myriad Pharmaceuticals; Novartis; Oncoinvent; Pfizer; PharmaMar; Phytolife Nutrition; Roche; Vifor Pharma
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer/Vital; Bristol Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Eisai; GlaxoSmithKline; Immunogen; Ingress Health; Intuitive Surgical; Johnson & Johnson; Karyopharm Therapeutics; Lilly; Merck; MSD Oncology; Mundipharma; Novocure; Oncoinvent; Pfizer; PharmaMar; Roche; Sanofi Aventis GmbH; Seagen; Sobi; Tubulis GmbH
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); IQvia (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); MSD Oncology (Inst); Mural (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG
 
Elena Ioana Braicu
Honoraria - Abbvie; AstraZeneca; North Eastern German Society for Gynecologic Oncology
Consulting or Advisory Role - Abbvie; GlaxoSmithKline; Immunogen; IQvia (Inst); MSD; Myriad Genetics; Pharma And; Torl Biotherapeutics; Tubulis GmbH
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Iqvia (Inst); MSD (Inst); Roche Molecular Diagnostics (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca
(OPTIONAL) Uncompensated Relationships - North Eastern German Society of Gynecologic Oncology (NOGGO eV)
 
Angela Relógio
Employment - TimeTeller
Stock and Other Ownership Interests - TimeTeller
Patents, Royalties, Other Intellectual Property - TimeTeller GmbH
(OPTIONAL) Uncompensated Relationships - TimeTeller